investor.aeoluspharma.com

Aeolus Pharmaceuticals - Investor Relations

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. We are developing a platform of a new class of broad-spectrum catalytic antioxidant. Compounds based on technology discovered at Duke University. Jun 8, 2017. May 15, 2017. View all releases ».

http://investor.aeoluspharma.com/

OVERVIEW OF investor.aeoluspharma.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

7

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.AEOLUSPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

May

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Thursday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.6 out of 5 with 8 reviews

5 star

1

4 star

5

3 star

1

2 star

0

1 star

1

Hey there! Start your review of investor.aeoluspharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.5 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128
160x160
192x192
256x256

CONTACTS AT INVESTOR.AEOLUSPHARMA.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

7

SSL

EXTERNAL LINKS

0

SITE IP

206.200.251.19

LOAD TIME

0.478 sec

SCORE

6.2

PAGE TITLE

Aeolus Pharmaceuticals - Investor Relations | investor.aeoluspharma.com Reviews

<META> DESCRIPTION

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. We are developing a platform of a new class of broad-spectrum catalytic antioxidant. Compounds based on technology discovered at Duke University. Jun 8, 2017. May 15, 2017. View all releases ».

<META> KEYWORDS

1 about us

2 corporate history

3 management team

4 board of directors

5 catalytic antioxidant program

6 data

7 development plan

8 education center

9 background on antioxidants

10 mechanism of action

CONTENT

Page content here

KEYWORDS ON PAGE

about us,corporate history,management team,board of directors,catalytic antioxidant program,data,development plan,education center,background on antioxidants,mechanism of action,dose,fractionation,gastrointestinal injury,about biodefense,about barda,faqs

POWERED BY

ASP.NET

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Aeolus Pharmaceuticals - Investor Relations | investor.aeoluspharma.com Reviews

https://investor.aeoluspharma.com

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. We are developing a platform of a new class of broad-spectrum catalytic antioxidant. Compounds based on technology discovered at Duke University. Jun 8, 2017. May 15, 2017. View all releases ».

INTERNAL PAGES

investor.aeoluspharma.com

1

Aeolus Pharmaceuticals - Email Alert Subscription

http://investor.aeoluspharma.com/profile.cfm

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. Step 1 of 3: Select Options. Quarterly and Annual Reports. Send me a stock update at the end of the trading day. Send me a stock update at the end of the week. Alert me when the stock changes more than. Current Stock Price is $0.100.

2

Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome (OTCBB:AOLS)

http://investor.aeoluspharma.com/releasedetail.cfm?ReleaseID=919616

Laquo; Previous Release. Next Release ». June 26, 2015. Barda Exercises $3 MM in Additional Contract Funding for Development of AEOL 10150 as Treatment for Acute Radiation Syndrome. MISSION VIEJO, CA. Aeolus Pharmaceuticals, Inc. A biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the. Announced today that the. Biomedical Advanced Research and Development Authority. US Department of Health and Human Services. Animal Rule" and for a pre-Eme...

3

Aeolus Pharmaceuticals - Investor Relations

http://investor.aeoluspharma.com/index.cfm

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. We are developing a platform of a new class of broad-spectrum catalytic antioxidant. Compounds based on technology discovered at Duke University. Aug 15, 2016. Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results. May 23, 2016.

4

Aeolus Pharmaceuticals - Press Releases

http://investor.aeoluspharma.com/releases.cfm

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results. Aug 15, 2016. Aeolus Pharmaceuticals to Present at LD Micro Invitational Conference. May 23, 2016. May 16, 2016. MISSION VIEJO, CA - (Marketwired) - 05/16/16 - In the news...

5

Aeolus Pharmateucticals to Present at LD Micro Invitational Conference (OTCBB:AOLS)

http://investor.aeoluspharma.com/releasedetail.cfm?ReleaseID=915206

Laquo; Previous Release. Next Release ». May 28, 2015. Aeolus Pharmateucticals to Present at LD Micro Invitational Conference. MISSION VIEJO, CA. Aeolus Pharmaceuticals, Inc. A biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the. David C. Cavalier. Chairman and Chief Financial Officer, will present at the. LD Micro Invitational Conference. Tuesday, June 2nd, 2015. Luxe Sunset Boulevard Hotel. BARDA"). The BARDA contract, worth up to.

UPGRADE TO PREMIUM TO VIEW 2 MORE

TOTAL PAGES IN THIS WEBSITE

7

OTHER SITES

investor.acusphere.com

404 Page Not Found

Error Page cannot be displayed. Please contact your service provider for more details. (13).

investor.adcarehealth.com

AdCare Health Services - Investor Relations - Overview

Investor Presentation 5.28.2015. AdCare Health Systems, Inc. (NYSE MKT: ADK) (NYSE MKT: ADK.PRA) is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. The Company currently owns, leases or manages for third parties. AdCare Facts at a Glance. Founded 1991, AdCare wen. 08/07/15 4:00 pm ET. Minimum 20 minute delay. There are currently no events scheduled. Sign up...

investor.adm-sharya.ru

Инвестиционный портал городского округа город Шарья

Представляю вашему вниманию Инвестиционный портал городского округа город Шарья. Он позволит объективно оценить привлекательность вложения капитала, а также найти надежных партнеров и принять решение о начале работы в нашем городе. ФАКТОРЫ КОНКУРЕНТОСПОСОБНОСТИ ГОРОДСКОГО ОКРУГА. Наличие значительного количества высококвалифицированных рабочих и инженерных кадров. Основным бюджетообразующим сектором экономики города является промышленность, железнодорожный транспорт, малый бизнес. Администрация города пр...

investor.adt.com

ADT Investor Information |

ADT Announces Appointment of Jeff Likosar as Chief Financial Officer. Read the Press Release. THE ADT CORPORATION FINANCIALS. View financial information about The ADT Corporation and Prime Security Services Borrower LLC. Login and View Documents. Access to our confidential financials and investor presentations requires a secure login. Submit a Financial Information Request. If you do not have access to view our documents, click here to access our registration request. Designed by Elegant Themes.

investor.advancedphotonix.com

PR Newswire

There is no web site at this address.

investor.aeoluspharma.com

Aeolus Pharmaceuticals - Investor Relations

About Cancer Radiation Therapy. Effect on different types of cancer. History of radiation therapy. About Acute Radiation Syndrome. Overview of Acute Radiation Syndrome. The Project BioShield Act. Draft BARDA Strategic Plan. FDA Guidance For Industry. You are here: Home. We are developing a platform of a new class of broad-spectrum catalytic antioxidant. Compounds based on technology discovered at Duke University. Jun 8, 2017. May 15, 2017. View all releases ».

investor.aetna.com

Reports, Filings & Statements - Investor Info | Aetna

Click Menu to close. Click to open Menu. Reports, Filings and Statements. Reports, Filings and Statements. View, print or download financial reports including earnings releases, financial supplements, guidance summaries, Form 10Qs and 10Ks. Snapshot of Aetna’s current financial metrics, ratios and trading statistics. Search Aetna’s SEC filings library and download the documents, including Section 16 filings, in pdf or html format. Reports, Filings, and Statements. You are now leaving the Aetna website.

investor.affiniagroup.com

AFFINIA - SEC Filings

SEC Filing Keyword Search. View SEC Groupings descriptions. View Section 16 Filings (3,4,5). Report of unscheduled material events or corporate event. Report of unscheduled material events or corporate event. Report of unscheduled material events or corporate event. Quarterly report which provides a continuing view of a company's financial position. Report of unscheduled material events or corporate event. Annual report which provides a comprehensive overview of the company for the past year.

investor.affymetrix.com

Affymetrix - About Affymetrix - Investors - Investors

Powered by Affymetrix Partners. Aug 07 15 4:00 pm ET. The stock price performance shown on the quote above is not necessarily indicative of future price performance. Q2 2015 Affymetrix Earnings Conference Call. 160;at 5:00 pm ET. Q2 2015 Affymetrix Earnings Conference Call. Wednesday, July 29, 2015 . 5:00 pm ET . Click here for webcast. Click here to add this event to your calendar. VP Investor Relations and Treasury. Affymetrix Reports Second Quarter 2015 Operating Results. SANTA CLARA, Calif.- (BU...

investor.afop.com

Alliance Fiber Optic Products, Inc. - Investor Relations

Skip to Main Content. Annual Report and Proxy. Proxy Statement - Annual Meeting. At Alliance Fiber Optic Products, Inc. (NASDAQ: AFOP). View all ». Jul 22, 2015. AFOP Reports Record Quarterly Sales in Q2 2015; Guidance for Year-Over-Year Increases of 33% in Q3 2015. Jul 6, 2015. AFOP Announces the Second Quarter Preliminary Results With Record Revenues, and the Second Quarter Conference Call Invitation.

investor.agenusbio.com

Agenus Bio Investor Center |

Activities What we do. Financial How we build value. News Our latest updates. Contact How to get in touch. July 24, 2015. GSK’s Malaria Vaccine Containing Agenus’ QS-21 Stimulon Receives Positive Opinion from European Regulators for Prevention of Malaria in Young Children in Sub-Saharan Africa. July 23, 2015. Agenus Reports Second Quarter 2015 Financial Results. July 20, 2015. Agenus Acquires Novel Antibodies to Immuno-oncology Target CEACAM1. July 16, 2015. Agenus to Report Second Quarter 2015 Financial...